Pharmaceuticals

Vaxneuvance Market 2026 expanding with pneumococcal vaccination demand

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Vaxneuvance Market By The End Of 2030?

The historical growth can be attributed to the broadening of routine pneumococcal vaccination programs, an increasing frequency of pneumococcal infections, enhanced understanding of vaccine-preventable conditions, progress in conjugate vaccine technology, and better availability of healthcare.

The anticipated expansion over the forecast period is linked to heightened investments in innovative vaccines, a greater emphasis on vaccinating the elderly, the broadening of national immunization schemes, an escalating demand for vaccines with broader protection, and wider acceptance within developing healthcare systems.

Significant trends expected during the forecast timeframe involve the increasing use of broad-spectrum pneumococcal vaccines, a heightened focus on preventing invasive diseases, expanding immunization coverage for both children and adults, the advancement of conjugate vaccine technologies, and an enhanced priority on protecting high-risk populations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20428&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Vaxneuvance Market?

The increasing incidence of pneumonia is anticipated to propel the expansion of the vaxneuvance market in the future. Pneumonia is a condition characterized by lung inflammation where air sacs become filled with fluid or pus, leading to symptoms like coughs, fevers, and breathing challenges. This widespread occurrence of pneumonia is influenced by factors such as viral and bacterial pathogens, compromised immune systems, environmental air pollution, and a growing elderly population, who are more prone to respiratory ailments. Vaxneuvance aids individuals by offering protection against pneumonia resulting from 15 strains of Streptococcus pneumoniae, thereby diminishing the likelihood of severe infections and associated issues. As an illustration, in 2024, data from the Johns Hopkins University, a US-based research university, showed that the average Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries reached 56%, marking a 2% rise from 54% in 2023. Consequently, the significant prevalence of pneumonia is a key driver for the growth of the vaxneuvance market.

Which Segment Classifications Shape The Vaxneuvance Market?

The vaxneuvance market covered in this report is segmented –

1) By Indication: Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media

2) By Distribution Channel: Pharmacies, Hospitals

3) By End User: Adults, Children, Geriatric Population

How Are Trends Impacting The Vaxneuvance Market?

Major entities operating in the vaxneuvance (pneumococcal conjugate vaccine) market are primarily focused on developing innovative offerings, such as advanced multivalent conjugate vaccines, to ensure broader protection against pneumococcal infections. These next-generation multivalent conjugate vaccines represent sophisticated vaccines engineered to safeguard against numerous strains of a pathogen by linking polysaccharides from each strain to a carrier protein, thereby boosting the immune response. For instance, in May 2025, Vietnam Vaccine JSC (VNVC), a US-based enterprise, unveiled the pneumococcal 15-valent conjugate vaccine (PCV15 or Vaxneuvance) to extend defense against multiple strains of Streptococcus pneumoniae that cause invasive and non-invasive diseases. The vaccine is designed for children from six weeks of age, as well as adults, delivering long-lasting immunity and helping to decrease the transmission of pneumococcal bacteria within the community. This introduction positions VNVC at the forefront of modern pneumococcal vaccination in Vietnam, enhancing its current portfolio of pneumococcal vaccines and reinforcing national immunization efforts.

Which Companies Are Expanding Their Footprint In The Vaxneuvance Market?

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

Read the full vaxneuvance market report here:

https://www.thebusinessresearchcompany.com/report/vaxneuvance-global-market-report

Which Regions Are Projected To Dominate The Vaxneuvance Market In The Coming Years?

North America was the largest region in the vaxneuvance market in 2025. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vaxneuvance Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20428&type=smp

Browse Through More Reports Similar to the Global Vaxneuvance Market 2026, By The Business Research Company

Vat Dyes Market Report 2026

https://www.thebusinessresearchcompany.com/report/vat-dyes-global-market-report

Video As A Service Vaas Market Report 2026

https://www.thebusinessresearchcompany.com/report/video-as-a-service-vaas-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795